Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study
Uloženo v:
| Název: | Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study |
|---|---|
| Autoři: | Mussini, Cristina, Cazanave, Charles, Adachi, Eisuke, Eu, Beng, Alonso, Marta Montero, Crofoot, Gordon, Chounta, Vasiliki, Kolobova, Irina, Sutton, Kenneth, Sutherland-Phillips, Denise, Urbaityte, Rimgaile, Ehmann, Alice, Scherzer, Jenny, de los Rios, Patricia, D’Amico, Ronald, Spreen, William, van Wyk, Jean |
| Zdroj: | AIDS Behav AIDS and behavior r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe Instituto de Investigación Sanitaria La Fe (IIS La Fe) |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2024. |
| Rok vydání: | 2024 |
| Témata: | Quality of life, Male, Adult, Pyridones, Anti-HIV Agents, HIV Infections, Heterocyclic Compounds, 4 or More Rings, Piperazines, Maintenance Chemotherapy, Humans, Emtricitabine, Cabotegravir, Patient Reported Outcome Measures, Tenofovir, Patient-reported outcome, Original Paper, Long-acting, Adenine, Rilpivirine, Middle Aged, Viral Load, Drug Combinations, Treatment Outcome, Patient Satisfaction, HIV-1, Female, Drug Combinations [MeSH], Tenofovir/analogs, Anti-HIV Agents/therapeutic use [MeSH], Adenine/therapeutic use [MeSH], Pyridones/administration, Patient Satisfaction [MeSH], Pyridones/therapeutic use [MeSH], Emtricitabine/administration, Piperazines [MeSH], Male [MeSH], Rilpivirine/administration, Drug Therapy, Combination [MeSH], Amides [MeSH], Anti-HIV Agents/administration, Adenine/analogs, Female [MeSH], HIV Infections/psychology [MeSH], Diketopiperazines [MeSH], Adult [MeSH], Rilpivirine/therapeutic use [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Tenofovir/administration, Middle Aged [MeSH], Viral Load [MeSH], Patient Reported Outcome Measures [MeSH], Heterocyclic Compounds, 3-Ring/therapeutic use [MeSH], Heterocyclic Compounds, 4 or More Rings/therapeutic use [MeSH], Emtricitabine/therapeutic use [MeSH], HIV Infections/drug therapy [MeSH], Maintenance Chemotherapy [MeSH], Tenofovir/therapeutic use [MeSH] |
| Popis: | SOLAR (NCT04542070; registered 2020-09-09) is a Phase 3b study that demonstrated the noninferior virological efficacy of switching to cabotegravir + rilpivirine long-acting (CAB + RPV LA) dosed every 2 months vs. continuing daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) over 12 months. Participants were randomised (2:1) to switch to CAB + RPV LA or to continue BIC/FTC/TAF. Patient-reported endpoints included treatment preference, treatment satisfaction (12-item HIV Treatment Satisfaction Questionnaire status version), acceptability of injections (Perception of Injection questionnaire [acceptability domain]) and three single-item questions exploring psychological challenges related to HIV treatment (fear of disclosure, adherence-related anxiety and reminder of HIV status). Of 670 participants, 447 participants switched to CAB + RPV LA and 223 continued BIC/FTC/TAF. Overall, 18% were female, median age was 37 years and 31% were non-White. At Month 12, CAB + RPV LA significantly improved treatment satisfaction vs. BIC/FTC/TAF (mean [95% confidence interval (CI)] change: + 3.36 [2.59, 4.13] vs. -1.59 [-2.71, -0.47]; p |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 1573-3254 1090-7165 |
| DOI: | 10.1007/s10461-024-04490-0 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39375290 https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=21551 https://repository.publisso.de/resource/frl:6523760 |
| Rights: | CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....08992456c73652b38f79b404fdca3570 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | SOLAR (NCT04542070; registered 2020-09-09) is a Phase 3b study that demonstrated the noninferior virological efficacy of switching to cabotegravir + rilpivirine long-acting (CAB + RPV LA) dosed every 2 months vs. continuing daily oral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) over 12 months. Participants were randomised (2:1) to switch to CAB + RPV LA or to continue BIC/FTC/TAF. Patient-reported endpoints included treatment preference, treatment satisfaction (12-item HIV Treatment Satisfaction Questionnaire status version), acceptability of injections (Perception of Injection questionnaire [acceptability domain]) and three single-item questions exploring psychological challenges related to HIV treatment (fear of disclosure, adherence-related anxiety and reminder of HIV status). Of 670 participants, 447 participants switched to CAB + RPV LA and 223 continued BIC/FTC/TAF. Overall, 18% were female, median age was 37 years and 31% were non-White. At Month 12, CAB + RPV LA significantly improved treatment satisfaction vs. BIC/FTC/TAF (mean [95% confidence interval (CI)] change: + 3.36 [2.59, 4.13] vs. -1.59 [-2.71, -0.47]; p |
|---|---|
| ISSN: | 15733254 10907165 |
| DOI: | 10.1007/s10461-024-04490-0 |